SLP
SLP 50 articles

Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push

benzinga.com·May 6

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

businesswire.com·May 6

Cadence Q1 Earnings Top Estimates, 2026 Revenue Outlook Raised

zacks.com·Apr 28

Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Rating of “Hold” from Brokerages

defenseworld.net·Apr 27

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

businesswire.com·Apr 21

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

businesswire.com·Apr 20

Simulations Plus: Better Quarter, Same Doubts

seekingalpha.com·Apr 15

Reviewing Smith Micro Software (NASDAQ:SMSI) & Simulations Plus (NASDAQ:SLP)

defenseworld.net·Apr 15

Simulations Plus: Down Substantially, Not An Automatic Buy

seekingalpha.com·Apr 12

Why Simulations Plus Stock Inched Higher Today

fool.com·Apr 10

Simulations Plus Q2 Earnings & Revenues Beat, Jump Y/Y, Shares Soar

zacks.com·Apr 10

Simulations Plus, Inc. (SLP) Q2 2026 Earnings Call Transcript

seekingalpha.com·Apr 9

Simulations Plus (SLP) Beats Q2 Earnings and Revenue Estimates

zacks.com·Apr 9

Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results

businesswire.com·Apr 9

JPMorgan Chase & Co. Boosts Holdings in Simulations Plus, Inc. $SLP

defenseworld.net·Apr 6

Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date

businesswire.com·Mar 26

Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling

businesswire.com·Mar 26

Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD

businesswire.com·Mar 3

ROSEN, A LONGSTANDING FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

newsfilecorp.com·Feb 11

Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations

businesswire.com·Feb 9

ROSEN, A TOP-RANKED LAW FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

newsfilecorp.com·Feb 9

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

prnewswire.com·Feb 8

ROSEN, A TOP RANKED LAW FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

newsfilecorp.com·Feb 6

SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

globenewswire.com·Feb 5

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

prnewswire.com·Feb 3

Simulations Plus to Participate in Upcoming Investor Conferences

businesswire.com·Feb 3

SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

globenewswire.com·Feb 2

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

newsfilecorp.com·Feb 1

ROSEN, A LONGSTANDING LAW FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

newsfilecorp.com·Jan 31

SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

globenewswire.com·Jan 30

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

prnewswire.com·Jan 29

SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

globenewswire.com·Jan 27

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

newsfilecorp.com·Jan 26

ROSEN, A LEADING NATIONAL FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

newsfilecorp.com·Jan 25

SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

globenewswire.com·Jan 24

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

prnewswire.com·Jan 23

Simulations Plus, Inc. (SLP) Analyst/Investor Day Transcript

seekingalpha.com·Jan 21

ROSEN, A LONGSTANDING LAW FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

newsfilecorp.com·Jan 21

Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day

businesswire.com·Jan 21

SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

globenewswire.com·Jan 20

Johnson Fistel Investigates Simulations Plus for Potential Securities Law Violations

globenewswire.com·Jan 20

ROSEN, LEADING INVESTOR COUNSEL, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

newsfilecorp.com·Jan 18

Simulations Plus Q1 Earnings Call Highlights

defenseworld.net·Jan 10

SLP Stock Crashes on Q1 Earnings Miss, Software Headwinds Hurt Sales

zacks.com·Jan 9

Simulations Plus, Inc. (SLP) Q1 2026 Earnings Call Transcript

seekingalpha.com·Jan 8

Market Today: GM's $7B EV Reset, Defense Stocks Pop, Hyundai's Robot Push

gurufocus.com·Jan 8

Simulations Plus Reports First Quarter Fiscal 2026 Financial Results

businesswire.com·Jan 8

Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Recommendation of “Hold” from Analysts

defenseworld.net·Dec 23

Simulations Plus (SLP) Upgraded to Strong Buy: Here's What You Should Know

zacks.com·Dec 18

Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development

businesswire.com·Dec 18